X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CRV431 (rencofilstat) is a cyclophilin A inhibitor currently undergoing mid-stage clinical trials with patients for the treatment of non-alcoholic steatohepatitis.
Lead Product(s): Rencofilstat
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CRV431
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2024
Details:
CRV431 (rencofilstat) is a Cyclophilin A inhibitor has been shown to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of Idiopathic Pulmonary Fibrosis, and has demonstrated antiviral activities towards HBV, HCV, and HDV.
Lead Product(s): Rencofilstat
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CRV431
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2023
Details:
Hepion intends to use the net proceeds from the offering for clinical development of CRV431 (rencofilstat), an oral drug candidate for nonalcoholic steatohepatitis (NASH) and viral hepatitis-induced liver disease.
Lead Product(s): Rencofilstat
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CRV431
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alliance Global Partners
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 29, 2023
Details:
CRV431 (rencofilstat) is a Cyclophilin A inhibitor has been shown to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of Idiopathic Pulmonary Fibrosis, and has demonstrated antiviral activities towards HBV, HCV, and HDV.
Lead Product(s): Rencofilstat
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: CRV431
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2023
Details:
CRV431 (rencofilstat) is a Cyclophilin A inhibitor has been shown to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards HBV, HCV, and HDV.
Lead Product(s): Rencofilstat
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CRV431
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2023
Details:
CRV431 (rencofilstat) is a Cyclophilin A inhibitor has been shown to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards HBV, HCV, and HDV.
Lead Product(s): Rencofilstat
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CRV431
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 22, 2023
Details:
Rencofilstat specifically binds cyclophilin isomerase enzymes and inhibits cyclophilin function. Rencofilstat is being examined as a potential therapeutic for multiple myeloma.
Lead Product(s): Rencofilstat
Therapeutic Area: Oncology Product Name: CRV431
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2023
Details:
CRV431 (rencofilstat) specifically binds cyclophilin isomerase enzymes and inhibits cyclophilin function, resulting in reduced inflammatory damage to the liver.. Rencofilstat has demonstrated efficacy in two distinct animal models of NASH and HBV replication.
Lead Product(s): Rencofilstat
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CRV431
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2023
Details:
CRV431 (rencofilstat) is a potent inhibitor of cyclophilins and is currently in clinical-phase development for the treatment of NASH, with the potential to play an important role in the overall treatment of liver disease - from triggering events through to end-stage disease.
Lead Product(s): Rencofilstat
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CRV431
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alberta Innovation Employment Grant
Deal Size: $0.3 million Upfront Cash: Undisclosed
Deal Type: Funding January 09, 2023
Details:
CRV431 (Rencofilstat), has been shown to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards HBV, HCV, and HDV through several mechanisms, in nonclinical studies.
Lead Product(s): Rencofilstat
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CRV431
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
